





# SHILPA MEDICARE LIMITED., RAICHUR

UNAUDITED FINANCIAL RESULTS FOR 2ND QUARTER & HALF YEAR ENDED 30.09.2011

Statement of Assets and Liabilities

(Rs.in Lakhs)

Particulars	(Unaudited)		(Unaudited)	
	Standalone		Consolidated	
	30.09.11	30.09.10	30.09.11	30.09.10
<b>Sources of Funds:</b>				
<b>01. Shareholders Funds:</b>				
a) Share Capital	480.48	480.48	480.48	480.48
b) Share Warrants	437.50	437.50	437.50	437.50
c) Share Application	0.00	0.00	0.08	0.00
d) Reserves and Surplus	24584.70	20408.15	23081.34	19295.33
	25502.68	21326.13	23999.40	20213.31
02. Foreign Currency Translation reserve	0.00	0.00	(8.77)	(8.04)
03. Loan Funds	4836.73	4328.75	5350.01	4976.84
04. Minority Interest	0.00	0.00	494.66	0.05
05. Deferred Tax Liabilities (Net)	1621.17	1542.69	-1539.60	1510.35
<b>Total</b>	<b>31960.58</b>	<b>27197.57</b>	<b>31374.90</b>	<b>26692.51</b>
<b>Application of Funds :</b>				
06. Fixed Assets (Net Block) Inc CWIP	13521.44	13254.28	18286.16	15137.74
07. Investments	3548.62	369.47	13.48	330.23
<b>08. Current Assets, Loans and Advances</b>				
a) Inventories	6498.87	4166.02	7296.70	4708.17
b) Sundry Debtors	2704.86	2116.46	2971.53	2508.30
c) Cash and Bank Balances	7304.72	7228.50	7781.27	7317.49
d) Loans and Advances	5919.34	5937.66	3388.88	3511.87
	22427.79	19448.64	21438.38	18045.83
<b>09. Current Liabilities &amp; Provisions</b>				
a) Liabilities	5103.19	2977.04	5760.16	3370.53
b) Provision	2434.08	2897.78	2978.74	3456.36
	7537.27	5874.82	8738.90	6826.89
	0.00	0.00	375.78	5.60
10. Miscellaneous Exp.to the extent not written off/ adjusted				
<b>Total Assets (Net)</b>	<b>31960.58</b>	<b>27197.57</b>	<b>31374.90</b>	<b>26692.51</b>

**Notes** 1. The above results is reviewed by the Audit Committee and approved at the Board of Director's meeting.

2. Figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform the figures of the current quarter.

3. Shareholder's complaints outstanding at the beginning of the quarter- Nil, received-22, resolved during the quarter-22 and pending Nil.

4. As per AS-17 reportable segment is only one i.e Bulk Drug & API, therefore, segment reporting is not applicable.

5. The Statutory Auditors have carried out the limited review of the above financial results.

6. From 7-9-2011 Nu-Therapeutics Pvt Ltd has become subsidiary of the Company

By the order of the Board of Directors  
M/S. SHILPA MEDICARE LIMITED

  
Vishnukant Bhutada  
Managing Director



Place: Hyderabad

Date: 12/11/2011